Canines spontaneously develop many cancers similar to humans -including osteosarcoma, leukemia, and lymphoma -offering the opportunity to study immune therapies in a genetically heterogeneous and immunocompetent environment. However, a lack of antibodies recognizing canine NK cell markers has resulted in suboptimal characterization and unknown purity of NK cell products, hindering the development of canine models of NK cell adoptive immunotherapy. To this end, we generated a novel antibody to canine NCR1 (NKp46), the putative species-wide marker of NK cells, enabling purification of NK cells for further characterization. We demonstrate that CD3 − /NKp46 + cells in healthy and osteosarcoma-bearing canines have phenotypic similarity to human CD3 −
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/NKp46
+ NK cells, expressing mRNA for CD16 and the natural cytotoxicity receptors NKp30, NKp44, and NKp80. Functionally, we demonstrate with the calcein release assay that canine CD3 inTrODUcTiOn Canines are a large animal model with spontaneous development of many cancers, including osteosarcoma, leukemia, lymphoma, glioblastoma, prostate cancer, and mammary cancer. Canines provide an outbred, immune competent disease model with genetic heterogeneity and a shared environment with humans (1) (2) (3) (4) . Testing of novel therapies in the canine model has educated the protocols for bone marrow transplants in humans and, more recently, has been used for the testing of immune therapies such as adoptive transfer of T-cells, HER2-Listeria vaccine, and Liposomal-muramyl tripeptide (L-MTP-PE; mifamurtide) (5) (6) (7) (8) (9) (10) (11) (12) . Despite the advantages of the canine model, NK cells are less well characterized in canines than mice and humans. The sequencing of the canine genome in the early 2000s revealed that like humans, canines have all of the natural cytotoxicity receptors along with NKp80 in their genome (13) (14) (15) (16) (17) . The primary inhibitory receptors that mediate licensing of NK cells are the Ly49 and KIR families of receptors, both of which recognize self through binding to MHC Class I. Mice have 16 Ly49 genes but only 2 KIR, whereas humans have 16 KIR genes but only a pseudogene of the Ly49 family (18) . The canine genome has no KIR and only one Ly49 gene, which has a predicted ITIM sequence suggesting that it functions as an inhibitory receptor (19) .
The identification of NK cells in canines has been met with seemingly conflicting results with some studies reporting CD3
− cell populations with NK cell properties, while others report CD3
+ cell populations with NK cell properties (20) (21) (22) (23) . Recently, Grondahl-Rosado et al. provided more clarity on the phenotype of canine NK cells using a cross-reacting anti-bovine antibody to NCR1 (NKp46), the putative species-wide marker of NK cells in mammals (13) (14) (15) (16) (24) (25) (26) (27) . Using this antibody, they identified a CD3
− /NKp46 + cell population in most canines that were also positive for Granzyme B. Furthermore, they confirmed that NKp46 is an activating receptor in canine. They also proposed that a CD3 − /NKp46 − /Granzyme B + cell subset may be a subset of canine NK cells (16, 17) . However, this anti-bovine NKp46 antibody is reported by the authors to not be suitable for sorting of CD3 − /NKp46 + cells, limiting the ability to further characterize the receptor expression and function of CD3 − /NKp46 + cells and this NKp46 − cell population (16, 17) . Additionally, expansion of canine NK-like cells, while more successful than ex vivo expansion of mouse NK cells, has been significantly less than reported in humans with expansions reported of up to 233-fold on average in 2-3 weeks (19-23, 28, 29) .
We sought to further characterize canine NK cells for use in osteosarcoma, where survival for metastatic human OS patients has largely remained stagnant at only 30% 5-year survival rate for the last 30 years (30) (31) (32) (33) . Canine OS is highly prevalent, with over 8,000 new diagnoses per year, and an average survival rate of only 1 year, allowing for the rapid testing of new therapeutics. While mouse models have provided important discoveries in OS pathogenesis and treatment, the spontaneous canine model of OS has been well characterized and is used as an additional important animal model of OS (1, 2, 34, 35) .
To this end, we defined canine NK cells by their expression of NKp46, using a novel anti-canine NKp46 antibody, and expanded canine NK cells on membrane-bound IL-21 expressing feeder cells. We report here the identification and characterization of NKp46 + and NKp46 − canine NK cells that have striking phenotypic and functional similarity to human NK cells. Canine NK cells from both healthy and OS-bearing canines expand 20,283-fold in 3 weeks enabling their use in testing NK cell therapies in the spontaneous canine model of OS.
MaTerials anD MeThODs
Peripheral Blood Mononuclear cell isolation
Animal research was conducted with approval from the Institutional Animal Care and Use Committee at MD Anderson Cancer Center (00001532-RN00). Healthy canine blood was obtained from established animal colonies at the following locations: Animal Blood Resources International, Hemopet, and Texas A&M University (IACUC Protocol: 2014-0294). Healthy canine blood from UC Davis was exempted from IACUC approval. All blood from client-owned animals was obtained with informed consent and was consistent with the established guidelines for safe canine blood draws. Blood from canine patients with suspected osteosarcoma who had not received chemotherapy within 1 month was obtained with informed consent from UC Davis under Protocol 18315. Osteosarcoma diagnosis was confirmed with radiographs or biopsies. Two out of the seven canine patients presented with potential chondroblastic osteosarcoma, with one of the two patients presenting with disease with alternative diagnosis of chondrosarcoma. Four out of the seven patients were females with ages ranging from 2 to 13 years old. Osteosarcoma tumor sites were frontal bone (1), metatarsal (1), tibia (1), femur (1), radius (2) , and ileal body (1) . Experiments using discarded buffy coats from normal human red blood cell (RBC) donations were conducted under MD Anderson Cancer Center IRB exemption PA13-0978.
Canine blood was drawn into lithium heparin tubes and was diluted upon receipt 1:5 in HBSS before Ficoll separation. Both canine and human blood were processed using Ficoll Plus (GE Healthcare; 17-1440-02), as described previously, and canine RBCs were lysed with RBC lysis buffer (Stem Cell Technologies, 07800) for 4 min on ice (36, 37) . TaBle 1 | sTr profile for canine cell lines used in this paper.   Marker name locus  chromosome  MDcK  Osca78  gray  Osca8  Osca40  abrams  Melanoma-12 cTac   Canine 1  FH3210  2  239, 305  285  281, 301  281, 285  241, 289  289, 309  297, 301  241   Canine 17  PEZ12  3  263, 297  271  271  294  260  271, 301  267, 271  275   Canine 2  FH3241  8  252, 264  264  256, 264  256, 264  260  260  260, 264  264   Canine 3  FH2004  11  170, 178  174  174  174  174  174  178, 222  243   Canine 16  FH2054  12  152, 172  160, 164  156  156  156, 160  160, 177  165, 169  165   Canine 4  FH2658  14  108, 116, 120  116, 128  109, 120  112  116  105, 120  116  116   Canine 5  FH4012  15  131, 135  131, 135, 140  123, 127  119, 123  127, 140  135  123, 127  123   Canine 6  REN214L11  16  154  154  150  154  154  150  155  154   Canine 13  WILMS-TF  18  275  295, 299  280, 290  283  295  291, 295  291  283, 288   Canine 7  FH2010  24  159  163  151, 159  151 
nK cell expansion
Five million canine PBMC were cocultured with 10 6 K562 Clone9.mbIL-21 in at day 0 (1:2 ratio), and additional K562s were added at a 1:1 ratio at days 7 and 14. Medium was supplemented with 6.1 ng/mL recombinant canine IL-2 (rcIL-2) (R&D systems, 1815-CL), and fresh medium was added every 2-3 days. For human IL-2 comparison expansions, human IL-2 was added at 100 IU/mL in place of canine IL-2. The concentration of human IL-2 was based on the dose of IL-2 used in previous publications on canine NK-like cells (21, 22, 39) .
For CD3 depletion experiments, canine PBMC was stained with CD3-FITC antibody and sorted for all PBMC that were CD3-negative. Sodium azide in CD3 antibody was reduced using Amicon Ultra-0. 5 
Flow cytometry
Blocking was performed in blocking buffer (50% FBS/PBS) with 0.1 mg of dog gamma globulin (Jackson ImmunoResearch, 0004-000-002) per 1,000,000 cells. Cells were stained with 200 ng/1,000,000 cells of mouse anti-canine NKp46 Clone 48A (isotype: IgG2a) or unconjugated TCRαβ/TCRγδ for 30 min, followed by goat anti-mouse IgG RPE (Jackson ImmunoResearch, 115-116-146) in 50% FBS/PBS, and finally with anti-canine TCRαβ/γδ (FITC/Alexa Fluor 488 when indicated; Peter Moore, UC Davis) and commercially available antibodies (Biorad) to canine CD3 (MCA1774F; clone CA17.2A12), CD8α (MCA1039A700; clone YCATE55.9), CD4 (MCA1038PECY7; clone YKIX302.9), CD21 (MCA1781A647; clone CA2.1D6), CD5 (MCA1037APC; YKIX322.3), and anti-human CD14 (MCA1568A647, MCA1568A700; TÜK4). Cells events were acquired on a LSR Fortessa. Flow cytometry gating was determined using cells stained with secondary only and single color controls were analyzed using FlowJo 7.6.5/10.
cell sorting
Canine cells were sorted on a FACSAria Sorter at the flow cytometry core facility (UT MD Anderson Cancer Center) using fourway purity with post-sort purity verification for expression of CD3 and NKp46 to generate ≥99.5% pure populations of CD3 − / NKp46 
/NKp46
− , and CD3 + expanded cells were sorted as described, rested overnight in IL-2, and cytotoxicity assays with calcein-AM based method were conducted in at least duplicate using 4 μg of calcein-AM/1,000,000 target cells (37) .
rT-Pcr/qPcr PCR cycling conditions were as followings: UDG activation: 50°C -2 min, Polymerase Activation: 95°C -2 min, Denature: 95°C -15 s, B-actin, NKp46, NKp30, Granzyme B, and Perforin -Anneal/Extend: 62°C -1 min; B-actin, Ly49, and CD16 -Anneal: 54°C -15 s, Extension: 72°C -1 min; B-actin, DNAM-1, NKp30, NKp44, NKG2D, and NKp80 at the same conditions as Ly49 and CD16 with the exception of Annealing at 59°C. Primer sequences for NKp30, NKG2D, Perforin, and Granzyme B were published and verified previously (22) . Primers for all other genes were made using Blast Primer software and Primer 3 with predicted specificity verified by Blast, as follows: Ly49: Forward-5′ TGGAAATGGGTTGACACTGA 3′, Reverse-5′ CTTTGGAAGGAGGCAGACAA 3′; NKp46: Forward-5′ CCGCATCCCAAAAATGACCC 3′, Reverse-5′ GGGCCTATGGGAAACTCCAC 3′; NKp80: Forward-5′ TCCC TGTCCTTACTGGTTTCTC 3′, Reverse-5′ TATTTGAGCC ATTCCGATG 3′; CD16: Forward-5′ CAGTGGAGAGTACAG GTGCC 3′, Reverse-5′ CCCTGCAGAAGTAGGAGCC 3′; DNAM-1: Forward-5′ AATGTCACGCTCACCTGTCA 3′, Reverse-5′ CGGTAAAGTCCCGAGTCAGA 3′; NKp44: For ward-5′ GAAGGAGGAAGACTCGGGATA 3′, Reverse-5′ GAAGGGGTGATGGTGGTAGA 3′; and B-actin: Forward-5′ CGAGCATCCCCAAAGTTCTA 3′, Reverse-5′ ATTCTCTT TCCCTCCCCTGT 3′. Primer specificity was verified by Melt Curve Analysis and agarose gel electrophoresis. Primer product sequences for new primers were verified using Qiaquick Gel Extraction Kit (Qiagen, 28704) and sequencing, as described previously. Primers were synthesized by Sigma-Aldrich. For qPCR for CD16, TaqMan Universal PCR Master Mix was used with B-actin (ThermoFisher Scientific, Catalog #: 4453320, Assay ID: Cf03023880_g1) and CD16 probes (ThermoFisher Scientific, Catalog #: 4448892 Assay ID: Cf02645051_m1) for 40 cycles according to the TaqMan Universal PCR Master Mix protocol. qPCR was determined using the 2 −∆∆C t method and normalized to B-actin, and relative to CD3
− /NKp46 + cells from the same donor.
Mass cytometry
Antibodies for mass cytometry were labeled with heavy metals using Maxpar-X8 labeling reagent kits (DVS Sciences) according to manufacturer's instructions and titrated for determination of optimal concentration. The antibodies and their respective heavy metal labeling include CD314/NKG2D-150Nd (Biolegend, 320802), CD3-151Eu (BioLegend, 300443), CD335/NKp46-154Sm (BioLegend, 331902), CD56-162Dy (BD, 559043), CD336/NKp44-163Dy (BioLegend, 325102), CD337/NKp30-164Dy (BioLegend, 325202) CD16-165Ho (DVS, 3165001B), CD159a/NKG2A-166Er (R&D, MAB1059), CD226/DNAM1-167Er (BioLegend, 337102), and CD159c/NKG2C-169Tm (R&D, MAB1381). Frozen primary and K562 Clone9.mbIL-21 expanded human NK cells were thawed 1 day prior to staining to allow for NK cell recovery overnight. After overnight recovery, 1.5 × 10 6 cells were stained with 2.5μM cell ID cisplatin (Fluidigm, 201064) in serum-free RPMI for 1 min for identification of viable populations. Subsequently, CyTOF staining was performed, as described previously, with the following minor modification: staining was performed in 5% FBS/0.01% sodium azide buffer in PBS (42) . Data were acquired on the CyTOF instrument (DVS Sciences).
clustering analysis
Clustering analysis of mass cytometry data was performed using spanning-tree progression analysis of density-normalized events (SPADE V3.0) software (43 − /NKp46 + cells from whole PBMC resulted in donor-dependent T-cell contamination that would be detrimental in an allogeneic setting, we depleted T-cells from PBMC using FACS-sorting, leaving B-cells and macrophages/monocytes in the culture. We previously observed with human NK cell expansion that these cells provide support for NK cell expansion without hindering cell purity (36) . Using this approach, the purity of CD3 − /NKp46 + cells significantly increased (median = 96.5 versus 40.7%; p = 0.01) and fold expansion was not affected with 2/3 donors demonstrating increased fold expansion with T-cell depletion ( Figure 3D ).
Function of cD3
− /nKp46 + cells
To determine whether CD3 − /NKp46 + cells are able to kill spontaneously, a hallmark of NK cell function expanded pure CD3 − / NKp46 + cells and CD3 + T-cells from the same donor were cultured with the canine osteosarcoma cell line, Gray. CD3 − /NKp46 + cells + cells at day 0 and CD3 − /NKp46 + fold expansion was observed (r = −0.81, p = 0.022, not shown), which led us to question whether Null cells were significantly contributing to the yield of NK cells at day 21. When null cells were included in the fold expansion calculations, the mean fold expansion was 50% less than when using NKp46 + cells only, representing at most a two-fold over-estimation of expansion rates if all of the Null cells represented an NK population ( Figure 5B) .
Next, we determined the phenotype of these Null cells. Null cells had similar expression of CD4 (PBMC: median = 4.7%, IQR = 2.01, 14.2, n = 8; day 21: 0.6%, IQR = 0.03, 1.91, n = 9) and CD5 (PBMC: median = 4.07%, IQR = 3.72, 6.45, n = 8; day 21: 3.5%, IQR = 0.38, 7.89, n = 9) compared to CD3 − /NKp46 + (NK) cells, but low expression of CD8 at day 0 (p = 0.02, Median = 3.1%, IQR = 0.9, 5.33, n = 7). However, similar to NK cells, CD8 expression in the null cells was significantly increased at day 21 (p < 0.001, day 21 = 54.6%) ( Figure 5C ). We questioned whether NKp46 might be inducible in these null cells as has been described in porcine NKp46 − cells (27) . found that NKp46 expression clusters into distinct NKp46 + and NKp46
− NK populations and NKp46 expression overlaps with CD16 expression (Figure 5H) (Figure 5I) . In contrast to canine Null cells, NKp46
− primary and expanded human NK cells had reduced expression of DNAM-1 (Primary -CD56 dim : p = 0.01, Expanded -CD56 dim : p = 0.01) (Figures 5E,I ). 
nK cells in canine Osteosarcoma
We obtained PBMC from canines that were not currently undergoing chemotherapy and found no difference in the percent of NK cells in OS-bearing canines compared to healthy controls ( Figure 6A) . Additionally, NK cells from OS patients had similar proliferation on K562 Clone 9.mbIL-21 feeder cells and cytotoxicity against three canine OS cell lines compared to healthy canines ( Figures 6B,C) .
DiscUssiOn
We sought to characterize canine NK cells and optimize their expansion for use as a comparative oncology model of NK immunotherapy of OS. To this end, we developed a monoclonal antibody specific to canine NKp46 and demonstrated that this antibody recognizes CD3 − /NKp46 + cells that have striking phenotypic and functional similarity to human NK cells -expressing all of the NCRs and secreting IFN-γ and TNF-α. These CD3 − / NKp46 + cells from both healthy and OS-bearing canines exhibit robust expansion with K562 Clone9.mbIL21 and canine IL-2 and are highly cytotoxic against OS. In addition, we identified a small population of NKp46 − NK cells that have reduced cytotoxicity but similar cytokine secretion and can be induced to express NKp46.
This antibody also identifies a subset of T-cells that are NKp46
+ .
In humans, NKp46
+ T-cells are rare, but NKp46 can be acquired upon activation in γδ T-cells (45, 46) . In bovines, NKp46
+ T-cells have functional similarity to bovine NK cells as they were able to kill a tumor cell line spontaneously unlike T-cells that did not express NKp46 (47) . We observed very little killing of the spontaneous OS lung metastasis cell line, Gray, by CD3 + canine T-cells, but it will be of interest to more fully characterize the phenotype and function of NKp46 + canine T-cells. Despite the low cytotoxicity of the T-cells against the OS cell line, it remains unknown whether the contaminating T-cells in K562 Clone9. mbIL-21 expanded cell cultures are capable of mediating graftversus-host disease. Substantial work in humans suggests that contaminating T-cells might mediate GvHD and be detrimental in an allogeneic transplant setting (48, 49) . Thus, to reduce this potential adverse effect by contaminating T-cells, we demonstrate that CD3-depleted PBMC can give rise to greater than 96% pure CD3 − /NKp46 + expanded NK cells. Spontaneous animal models of cancer for the study of NK cell therapies in a syngeneic setting have to date remained elusive due to difficulty in expanding NK cells in other species outside of human and the high cost of primate research. Instead, preclinical models of adoptive NK cell therapy have relied largely on infusing human NK cells into xenogeneic mouse models which lack a complete tumor microenvironment and an intact immune system that may influence the effectiveness of immune-based therapies (36, 50) . We report here an improved expansion platform for canine NK cells on K562 Clone 9.mbIL-21 feeder cells obtaining a median fold expansion of over 20,000 in 3 weeks when supplemented with canine IL-2. To the best of our knowledge, this is the largest fold expansion of NK cells from any mammal outside of human and is significantly greater than previously reported expansions of NK-like cells in canine (20, 22) . Previous expansions of canine CD3 − NK-like cells have reported an average fold expansion of 140-fold in 3 weeks using cytokine alone (IL-2 and IL-15), 233-fold expansion in 2 weeks with EL08-1D2 feeder cells following CD5 depletion, and 90-fold expansion with K562 feeder cells and soluble IL-2, IL-15, and IL-21 in 3 weeks (20, 21) . It will be of future interest to determine if the improved expansion of canine NK cells with mbIL-21 over mbIL-15 is also due to an increase in telomere length as we have previously demonstrated for human NK cells (36) . Surprisingly, we found that CD3 − /NKp46 + cells displayed cytotoxicity against the MDCK cells used as normal controls. MDCK can undergo tumorigenic transformation, which could induce the expression of activating ligands (44) . In addition, the existence of only one Ly49 gene and no KIRs in the canine genome raises the question of whether the single Ly49 can bind to all dog leukocyte antigens (DLA) (51), which could increase NK cell killing in the allogeneic setting. It will be necessary to better define canine Ly49-DLA interactions in order to predict these responses.
Similar Figure 5F) (17) . NKp46 − NK cells are not unique to canines but have been previously reported in both porcine and humans, where NKp46 expression also discriminates human NK cells with reduced cytotoxicity. In contrast to our data in canine, porcine NKp46 expression discriminate porcine NK cells with different IFN-γ secretion but not cytotoxicity (27, 52) . Similar to porcine NKp46 − NK cells, NKp46 could be induced in canine NKp46 − cells; however, NKp46 has not been inducible in human NKp46
− cells (27) . This may be due to differences in the regulation of NKp46 expression across species, where it is inducible in some species' (porcine and canine) NK cells, but not in human, or NKp46 expression may require specific signals that have not been described yet (52) .
We found striking phenotypic similarity between canine NKp46 − null cells and both primary and K562 Clone9. Contrary to human OS patients, we found no significant difference in circulating NK cells in canine OS compared to healthy canines (53) . It will be of future interest to determine if these primary NK cells are functionally impaired, which would be facilitating tumor growth and has been found in several human cancers (54, 55) . However, our data demonstrate that expanded NK cells from canine OS patients are active against OS, both primary and metastatic cell lines. This parallels findings in human OS where cytokine-activated NK cells from human OS patients have similar cytotoxicity against both OS cell lines and autologous patient-derived biopsies compared to healthy controls (56) . Based on these findings, autologous NK cells may be effective in canine OS.
In summary, our study furthers the understanding of the canine NK cell phenotype and function. Furthermore, we describe the largest expansion of NK cells from another mammal besides humans, using K562 Clone 9.mbIL-21 feeder cells and canine IL-2. These mbIL-21 expanded NK cells are highly cytotoxic against OS cell lines, suggesting potential for immunotherapy of dogs with OS and potential for therapeutic use in other canine cancers such as lymphoma, leukemia, melanoma, and glioblastoma. This approach will allow for the study of NK cell therapy in an immune-intact, outbred, and spontaneous animal model. Many of these cancers progress rapidly in canines, allowing for rapid testing of NK cell therapies, which is of particular interest in rare and pediatric cancers such as OS where trial accrual is slow. These results support the development of canine NK cell trials to help prioritize the most promising treatment regimens for human clinical trials. Of particular interest is a trial of intratumoral injection of canine NK-like cells expanded on K562 Clone9.mbIL-21 feeder cells after radiation therapy in canine OS that is currently underway (UC Davis, Michael Kent & Bob Canter). The effectiveness of canine NK cells in combination with other agents, such as cytokines, chemotherapy, and antibodies, will be of particular interest.
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